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บทคดัยอ่  
วตัถปุระสงค:์ เพื อประเมนิสมการที เหมาะสมที สุดสําหรบัคนไทยในการคํานวณ
ค่าการกําจดัยาดจิ๊อกซนิ ซึ งได้แก่ Sheiner, Sheiner 1977, Jusko, Yukawa 
(1997 และ 2001), Bauer, Nagaraja, Nakajud และสมการสําหรบัทํานายระดบั
ยาในเลอืด ไดแ้ก ่Bauman วิธีการศึกษา: ทําการศึกษาโดยการเจาะวดัระดบัยา 
ดจิ๊อกซินในเลอืดผู้ป่วยที รบัประทานยาอย่างสมํ าเสมอติดต่อกันเป็นเวลาอย่าง
น้อย 7 วนั จํานวน 37 ราย จากโรงพยาบาลชุมชน 3 แห่ง ระหว่างมกราคมถึง
กนัยายน พ.ศ. 2556 ผลการศึกษา: พบวา่ผูป้่วยส่วนใหญ่เป็นเพศหญิง (รอ้ยละ 
67.6) มอีายุเฉลี ย 64.32 ± 10.4 ปี นํ าหนักเฉลี ย 52.03 ± 10.9 กโิลกรมั มภีาวะ
ไตวายอยู่ในระยะที  3 (Clcr เท่ากบั 30 – 59 ml/min) (ร้อยละ 62.2) ใช้ยาดจิ๊อก
ซนิเพื อรกัษาภาวะ Atrial fibrillation (รอ้ยละ 56.8) ได้รบัยาดจิ๊อกซนิขนาด 125 
ไมโครกรมั วนัละ 1 คร ั  ง (รอ้ยละ 67.6) ผูป้่วยสว่นใหญ่มรีะดบัยาดจิ๊อกซนิในเลอืด
อยูใ่นช่วงการรกัษา (0.5 – 2.0 ng/ml) (รอ้ยละ 78.4) พบว่าสมการของ Yukawa 
2001 มคีวามถูกตอ้งและไม่มอีคตใินการทํานายระดบัยาดจิ๊อกซนิในเลอืด ซึ งมคี่า 
mean prediction error (MPE) = 0.08 (95%CI = -0.05 - 0.21) และ mean 
absolute error (MAE) = 0.21 (95%CI = 0.11 - 0.31) สรปุ: สมการของ 
Yukawa 2001 เหมาะสมสําหรบัการคํานวณค่าพารามเิตอร์ทางเภสชัจลนศาสตร์
ของยาดจิ๊อกซนิ คอืค่า clearance เพื อนําไปใช้ทํานายระดบัยาดจิ๊อกซนิในเลอืด
ต่อไป  
คาํสาํคญั: ดจิ๊อกซนิ การทํานาย ระดบัยาดจิ๊อกซนิในเลอืด, สมการ  
Abstract 
Objective: To evaluate the calculation equation that was most suitable for 
predicting serum digoxin in Thai patients. The equations included those of 
Sheiner, Sheiner 1977, Jusko, Yukawa (1997 and 2001), Bauer, Nagaraja, 
Bauman and Nakajud. Materials and Method: Blood samplings were 
collected from 37 patients who received digoxin at least 7 consecutive days 
at 3 community hospitals from January and September 2013. Results: The 
results revealed that most of the patients were female (67.6%), with an 
average age of 64.32 ± 10.4 years, average weight of 52.03 ± 10.9 kg, 
renal function in stage 3 (Clcr 30 – 59 ml/min) (62.2%), having atrial 
fibrillation (56.8%) and receiving digoxin dose of 125 mcg/day (67.6%). 
Most of serum concentrations were in therapeutic level (0.5 – 2.0 ng/ml) 
(78.4%). It was shown that Yukawa 2001 equation had no bias [mean 
prediction error = 0.08 (95%CI = -0.05 - 0.21)] and more accuracy [mean 
absolute error = 0.21 (95%CI = 0.11 - 0.31)] than the other equations. 
Conclusion: The Yukawa 2001 equation was the most suitable method to 
be used along with the provision of pharmaceutical care for patients using 
digoxin at digoxin clinic in community hospitals.  
Keywords: digoxin, prediction, serum digoxin, equation  
 
Introduction
Digoxin is an inotropic agent primarily used to treat heart 
failure (HF) and atrial fibrillation (AF).1 Since digoxin has a 
narrow therapeutic index (0.5 – 2.0 ng/ml), serious toxic 
effect may occur even if the drug is used in a recommended 
dose as it has a large inter-patient variability in its 
pharmacokinetic property. Digoxin had a large volume 
distribution and is renally excreted. Factors associated with 
inter-patient variability included age, weight, disease state 
and renal function.2,3 Co-administration of interacting drug 
such as amiodarone, verapamil, spironactone increases 
serum digoxin concentration. Serum digoxin monitoring is an 
important process for optimizing digoxin therapy. However, in 
Thailand, particularly at the community hospital, due to 
financial barriers, digoxin concentration monitoring is not 
always accessible in a routine practice.4 Many equations 
have been developed to predict serum digoxin; nevertheless, 
there was a lack of predictive performance evaluation of 
these equations for Thai patients using digoxin. The purpose 
of this study was to evaluate the equations most suitable for 
calculating digoxin clearance including those of Sheiner, 
Sheiner 1977, Jusko, Nakajud, Yukawa (1997 and 2001), 
Bauer, Nagaraja and an equation for predicting serum 
digoxin concentrations of Bauman.  
  
Materials and Methods 
Data source 
The present study was a cross-sectional observational 
study. The study protocol was approved by the Ethic 
Committee of Human Research of Mahasarakham University 
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(0133/2555). The electronic medical records of patients who 
received digoxin tablet over a 9-month period (January to 
September 2013) were used to screen for eligible patients. 
This screening procedure yielded 74 potentially eligible 
patients. The medical records of these patients were then 
reviewed following inclusion criteria: age 18 years or older, 
receiving stable oral digoxin dose at least 1 month, receiving 
digoxin at least 7 consecutive days, and having serum 
digoxin concentration of  0.3 ng/ml. The patients had given 
informed consent. Patients were excluded from the study if 
any of these exclusion criteria were met: the presence of 
end-stage renal function (GFR ≤ 15 ml/min/1.73 m2), having 
active hepatitis, biliary obstruction, or severe liver disease, or 
having a serum digoxin concentration of < 0.3 ng/ml.  
 
Digoxin assay 
All blood samples were drawn before the morning dose 
for assay (22 – 24 hours after previous dose). Serum digoxin 
concentrations were determined by the Chemiluminescent 
Microparticle Immunoassay (Abbott Architect Digoxin 
System). The lower limit of detection for this assay is 0.3 
ng/ml and ≤ 10% total coefficient of variation (CV). 
Spironolactone and canrenone does not interfere with the 
determination of digoxin concentration by this method.  
 
Description of the prediction methods 
Steady state serum digoxin concentrations (SDC) was 
calculated by using the digoxin clearance from equations 
including those of Sheiner, Sheiner 1977, Jusko, Nakajud, 
Yukawa (1997 and 2001), Bauer, and Nagaraja. The 
Bauman equation was used to predict serum digoxin 
concentrations. 
Steady state digoxin serum concentration was calculated 
by using the following equation: 
  
Cave-sspredicted = [MD * F] / [Cl * ]  
 
Digoxin clearance was predicted by 8 equations as 
follows: 
 
Sheiner:  
No CHF: CL(L/day) = [Clcr(ml/min/kg)] + 0.8] * BW(kg) * (factors) * 1.44  
CHF: CL (L/day) = [0.9(Clcr(ml/min/kg))] + 0.33] * BW(kg) * (factors) * 1.44  
Jusko: 
CL = [(A * CrCl) + B] * C  
Bauer:  
CL [L/h] = [2.37 + 0.0797*Clcr] * 0.68
VER
 * 0.511
QUI
 
CL (L/h) = 0.795 * Scr 
–0.650
 * WT 
0.533
 * 0.71
 VER
 * 0.595 
QUI
 
Shiener 1977:  
CL (L/h) without CHF = 0.06 * CrCL+0.05 * TBW 
CL (L/h) CHF = 0.053 * CrCL + 0.02 * TBW  
Yukawa 1997:  
CL (L/day) = 106.0[1-0.00475*AGE]*TBW
0.310
*Scr
-0.569
* 0.858
GEN
 * 0.895
SPI
 * 0.813
CHF
*0.824
DFAC 
CL (L/day) = 29.6*CLcr0.526*0.9
SPI
*0.814
CHF
*0.833
DFAC
 
Yukawa 2001:  
CL (L/h) = [0.036 * TBW + 0.112*CLcr] * 0.77
SPI
 * 0.784
CCB
 
Nagaraja:  
CL = 0.053 * CLCR + 2.06 
Nakajud:  
CL/F (L/hr) = 0.122 * CrCl 
 
Digoxin serum concentrations were predicted by 
equations as follows: 
 
Bauman:  
Cpe = 1.345 + [0.287 * Dose] – [0.007 * Clcr] – [0.011 * IBW] 
 
where,   
Cave-sspredicted = predicted concentration at steady state, MD = Maintenace dose, F = 
Bioavailability, CL = Digoxin Clerance,  = Dosing interval, CHF = congestive heart failure, CrCl = 
normalized creatinine clearance [ml/min], BSA = Body surface area (square meters), A = 0.88, for 
patient with Acute CHF, otherwise=1, B = 23, for patient with Acute CHF, otherwise = 40, C = 
correction factor for interacting drugs (quinidine = 0.65, spironolactone = 0.75, verapamil = 0.7), 
VER = 1 for combination with verapamil, 0 for otherwise, GEN = 1 for combination with gentamicin, 
0 for otherwise, QUIN = 1 for combination with quinidine, 0 for otherwise, Scr = serum creatinine, 
SPI = 1 for combination with spironolactone, 0 for otherwise, WT = total body weight [kg], AGE = 
age (year), DFAC = 1 for half a tablet, 0 for one tablet, CHF = 1 for patient with Acute CHF, 0 for 
otherwise, CCB = 1 for combination with calcium antagonist (diltiazem, nifedipine, verapamil), 0 for 
otherwise, Cpe = Expected plasma concentration, Clcr = Creatinine clearance, Dose = 
Maintenance dose of digoxin, IBW = Ideal body weight.  
 
Statistical analysis  
Continuous data were presented as mean  SD. 
Categorical data were presented as numbers and 
percentages. The correlations between the observed and the 
predicted serum digoxin concentrations by the different 
equations were tested by Pearson’s correlation coefficient. 
The predictive performance of each equation was also 
evaluated by calculating the mean prediction error (MPE) 
and mean absolute error (MAE). MPE, which describes the 
bias that may be present, and MAE, a measure of accuracy, 
were calculated by the following equations:  
 
MPE = 
1
n
∑  
cpei - Cpoi
Cpoi
 ni=1  
 
MAE = 
1
N
∑  Cpoi- Cpei 
N
i=1  
 
Where,   
n = number of non-missing data points 
N = number of non-missing data points 
Cpei = Expected concentration 
Cpoi = Observed concentration 
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Results  
From a total of 74 patients, 37 were excluded from the 
analysis: digoxin was discontinued by physician in 9 patients, 
6 patients were lost follow up, 2 patients had GFR of < 15 
ml/min and 20 patients had digoxin concentrations of < 0.3 
mcg/ml. The remaining 37 patients had digoxin 
concentrations that met the inclusion criteria. Of these 37, 25   
  
 
 Table 1  Baseline characteristics.  
Characteristics Number (%) (N = 37) 
Female gender 25 (67.6) 
Age [years], mean ± SD 64.32 ± 10.4 
Weight [kg], mean ± SD 52.03 ± 10.9 
Height [cm], mean ± SD 156.32 ± 6.1 
Indication 
  Atrial fibrillation 
 
34 (91.9) 
  Congestive heart failure, 3 (8.1) 
Digoxin dose [mcg/day] 
  125 
  250 
 
25 (67.6) 
12 (32.4) 
Potassium concentrations 
  Low 
  Normal 
 
10 (27.0) 
27 (73.0) 
Renal function (ml/min) 
  Clcr  90  
  Clcr 60 – 89  
  Clcr 30 – 59  
  Clcr 15 – 29  
 
1 (2.7) 
7 (18.9) 
23 (62.2) 
6 (16.2) 
Comorbidity 
  Hypertension 
  Diabetes mellitus 
  Thyrotoxicosis 
  Hyperlipidemia 
  Mitral stenosis 
  Gout 
  Ischemic heart disease 
  Asthma 
 
10 (27.0) 
7 (18.9) 
3 (8.1) 
2 (5.4) 
2 (5.4) 
1 (2.7) 
1 (2.7) 
1 (2.7) 
Concomitant drug  
  Diuretics 16 (43.2) 
  ACEIs 12 (32.4) 
  Beta-blockers 10 (27.0) 
  Calcium channel blockers 10 (27.0) 
  Antiplatelet agents  24 (64.9) 
  Anticoagulants  18 (45.9) 
  Vitamins and minerals 22 (71.0) 
  Lipid-lowering agents  14 (43.2) 
  Antidiabetics  6 (16.2) 
  Proton pump inhibitors  7 (18.9) 
  Benzodiazepines 3 (8.1) 
  Antithyroid agents 3 (8.1) 
  Nitrates 69 (16.2) 
  Uricosuric agents  1 (2.7) 
  Xanthine oxidase inhibitors 1 (2.7) 
  Corticosteroids inhalants 1 (2.7) 
  Beta2 agonists 1 (2.7) 
  Xanthine derivatives 1 (2.7) 
  Tricyclic antidepressants 1 (2.7) 
 
 
were female (67.6%) (Table 1). Thirty-four patients (91.9%) 
had indication for atrial fibrillation. Twenty-five patients 
(67.6%) were receiving digoxin 125 mcg once daily, while 12 
patients (32.4%) were receiving 250 mcg once daily. 
Laboratory analyses revealed that 27 patients (73.0%) had a 
normal potassium concentration, and 23 patients (62.2%) 
had creatinine clearance range between 30 and 59 ml/min. 
There were 10 patients (27.0%) having underlying 
hypertension and 24 patients (64.9%) receiving antiplatelet 
agents.  
In terms of digoxin concentrations, the steady state 
digoxin concentrations for analysis ranged from 0.3 to 1.7 
ng/ml (mean  SD:  0.73  0.32 ng/ml).  
 
 
Correlation between the observed and predicted digoxin 
concentration  
Overall, 29 out of 37 measured serum digoxin 
concentrations (78.4%) were in the therapeutic range (0.5 – 
2.0 ng/ml) and 8 measured concentrations (21.6%) were in 
the sub-therapeutic range (< 0.5 ng/ml). Signs and 
symptoms of disease of all patients were controlled and 
there were also no signs and symptoms of digoxin 
intoxication and adverse events. The mean  S.D., minimum 
and maximum measured serum digoxin concentrations were 
0.73  0.32, 0.3 and 1.7 mcg/ml, respectively. The minimum 
– maximum observed and predicted serum digoxin 
concentrations are shown in Table 2.  
 
 
 Table 2 The minimum – maximum of observed and 
predicted serum digoxin concentrations (SDC).   
Equation/variable 
Minimum – Maximum 
SDC (mcg/L) 
Mean  SD (mcg/ml) of 
SDC 
Observed concentrations 0.3 – 1.7 0.73 ± 0.32 
Sheiner 0.6 – 6.30 1.88 ± 1.07 
Jusko 0.53 – 2.63 1.11 ± 0.46 
Bauer 0.39 – 1.90 0.81 ± 0.33 
Sheiner1977 0.47 – 2.17 0.94 ± 0.39 
Yukawa1997 0.32 – 1.23 0.55 ± 0.18 
Yukawa2001 0.32 – 2.56 0.79 ± 0.41 
Nagaraja 0.55 – 2.40 1.08 ± 0.43 
Nakajud  0.49 – 4.62 1.36 ± 0.78 
Bauman -0.6 – 0.78 0.48 ± 0.17 
 
Figure 1 shows the linear-regression analyses between 
the observed and predicted serum digoxin concentrations for 
the different tested equations. The Nakajud equation showed 
the strongest correlation (r2 = 0.576; P <.001) in comparison 
to the other tested equations (with r2 of all other equations in 
the range of 0.47 to 0.52). The Bauman equation which was 
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used to predict digoxin serum concentrations had an r2 of 0.199 (P-value = 0.06).  
 
   
(A)  (B) (C)  
   
   
(D) (E) (F) 
   
   
(G) (H) (I) 
 
 Figure 1  Linear-regression analyses showing the correlation between the observed and predicted SDC (ng/ml) according to; 
the Sheiner equation (A), the Jusko equation (B), the Bauer equation (C), the Sheiner 1977 equation (D), the Yukawa 1997 equation (E), the 
Yukawa 2001 equation (F), the Nagaraja equation (G), the Nakajud equation (H) and the Bauman equation (I). Note that the Nakajud equation 
shows the best correlation in the linear-regression.  
 
 
A comparison between the measured and predicted 
SDCs for the different equations were also tested by the 
mean absolute error (MAE) and mean prediction error 
(MPE), which demonstrated the lowest values, meaning 
higher accuracy and less bias (Table 3). The MAE and MPE 
(with 95% confidence interval) for each equation were more 
likely to over-predict except the Bauman equation which had 
a lower prediction error. However the Yukawa 2001 equation 
showed the best predictive performance.  
 
 
 Table 3  Mean prediction error (MPE) and mean absolute 
error (MAE).  
Equations MPE (95%CI) MAE (95%CI) 
Sheiner 1.67 (1.28 - 1.92) 1.15 (0.87 - 1.44) 
Jusko 0.65 (0.45 - 0.85) 0.41 (0.31 - 0.51) 
Bauer 0.21 (0.07 - 0.36) 0.20 (0.10 - 0.30) 
Sheiner1977 0.39 (0.22 - 0.56) 0.27 (0.17 - 0.37) 
Yukawa1997 -0.16 (-0.26 - -0.06) 0.23 (0.13 - 0.33) 
Yukawa2001 0.08 (-0.05 - 0.21) 0.21 (0.11 - 0.31) 
Nagaraja 0.62 (0.42 - 0.82) 0.38 (0.28 - 0.48) 
Nakajud  0.93 (0.70 – 1.15) 0.63 (0.51 - 0.83) 
Bauman -0.26 (-0.36 - -0.15) 0.27 (0.17 - 0.37) 
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Discussion and Conclusion  
 
In current study measuring predictive performance using 
mean absolute error (MAE) and mean prediction error 
(MPE), the Yukawa 2001 equation had lowest bias (MPE = 
0.08, 95%CI = -0.05 - 0.21) and provided the most accuracy 
(MAE = 0.21, 95% CI = 0.11 - 0.31) compared to the other 
equations. As shown in Table 2, the performance of the 
Sheiner, Sheiner 1977, Jusko, Nakajud, Yukawa (1997 and 
2001), Bauer, and Nagaraja tended to over-predict serum 
digoxin concentration because these equation were created 
from heart failure that had a lower digoxin clearance than 
atrial fibrillation who were subjects in current study.  
Most of serum digoxin concentrations were in therapeutic 
level (0.5 – 2.0 ng/ml) (78.4%). Measured serum digoxin 
concentration in current study (0.73  0.32 mcg/L, range: 0.3 
– 1.7 ng/ml) was lower than previous study because most of 
patients were outpatients with atrial fibrillation. This finding 
suggested that serum digoxin concentration in admitted 
patients with congestive heart failure were higher than in 
patients with atrial fibrillation and serum digoxin 
concentration in in-patients were higher than in outpatients 
that were found in previous studies.5,6 Several studies have 
found that congestive heart failure is an important factor in 
estimating digoxin clearance. Sheiner et al found that digoxin 
clearance was lower in patients with congestive heart failure 
than in patients without congestive heart failure.6 Naffs et al 
found that digoxin clearance was lower in patients with 
congestive heart failure than in patients with atrial fibrillation 
(2.88  1.226 vs 4.26  2.16 L/h).7 Congestive heart failure 
was known to cause reduced gastric emptying and 
malabsorption of drug.8 From linear-regression analysis in 
our study, the observed and predicted serum digoxin 
concentrations from most equations were correlated. This 
indicates that the predicted concentration was closely 
correlated to the observed concentration.  
In current study, the predictive performance of Sheiner 
1977 was relatively low with MAE of 0.27 (95%CI = 0.17 - 
0.37) and MPE of 0.39 (95%CI = 0.22 - 0.56), showing less 
accuracy and more bias than previous study. El-sayed et al9 
found that Sheiner 1977 equation in CHF had ME = -0.03 (-
0.08 – 0.01), MSE = 0.01 (0.01 – 0.02) and non-CHF had 
ME = -0.05 (-0.09 – 0.01), MSE = 0.03 (0.02 – 0.04) 
because of difference in method to evaluate creatinine 
clearance. El-sayed used the 24-hr urine collected method to 
evaluate creatinine clearance while our current study 
calculated creatinine clearance by using Crockcroft and 
Gault equation. The performance of Jusko, Bauer, Yukawa 
1997, Nagaraja and Nakajud equation tended to over-predict 
serum digoxin concentration because the equation was 
created from in-patients with congestive heart failure who 
were admitted whereas most of the patients from the study 
were outpatients with atrial fibrillation known to have serum 
digoxin concentration lower than in admitted patients with 
congestive heart failure.5,7,8,10-12 The Yukawa 2001 equation 
was found to have MPE = 0.08 (95% CI = -0.05 - 0.21) and 
MAE = 0.21 (0.11 - 0.31) that were similar to previous study 
because Yukawa equation was performed by adjusting 
several factors such as body weight, and drug co-
administration (spironolactone, diltiazem, nicardipine, 
nifedipine and verapamil) in the equation.13 The Bauman 
equation predictive performance was reflected as MAE = 
0.27 (95% CI = 0.17 - 0.37) and MPE = -0.26 (95% CI = -
0.36 – -0.15)  which was close to the result from Buaman 
(root mean square error of 0.375). However this result was 
less accurate and more biased than Muzzarelli study 
conducted in Caucasians (root mean square error of 0.17), 
implying that these differences might be due to different 
ethnic groups,14,15 which were also related to 
pharmacogenetic expression. This could be explained by 
previous studies showing that the patients with multidrug 
resistance protein1 (MDR1) genotype C3435T SNP 
homozygous TT had 20% serum digoxin concentration 
higher than heterozygous CT and homozygous CC [TT > CT 
> CC]. The genotype TT was found in 20% Chinese, 24% 
German, 28% British but not found in Ghanaian16-20, however 
there was no such study in Thai patients.  
Our study was conducted in a routine healthcare practice 
and patient compliance was assessed before collecting 
blood sample. There were a few limitations of the study. The 
current study used population digoxin bioavailability 
parameter values for calculation because there were no 
bioequivalence data from the digoxin brand used the 3 
community hospitals. However the 3 hospitals used the 
same brand. Therefore, future study should use digoxin 
bioavailability from a drug company. In addition, the study 
recruited too small sample size. The number of eligible 
subjects should be increased. Patients with congestive heart 
failure should also be included in future studies.  
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Conclusion  
The Yukawa 2001 equation showed the best predictive 
performance which could be incorporated to the provision of 
pharmaceutical care at digoxin clinic in community hospitals 
for better care of all patients using digoxin. This finding could 
help reduce financial problems of those patients who cannot 
access standard routine digoxin serum monitoring.  
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